Trofosfamide Versus Adriamycin in Elderly Patients With Soft Tissue Sarcoma (STS)

Inclusion Criteria: * Histologically established metastatic (N+ or M1 = stage IV) or non-resectable soft tissue sarcoma· * Grading II/III (Guillou et al. J Clin Oncol 1997) * At least 1 measurable tumor parameter according to RECIST criteria * Evidence of progression or primary manifestation (except osseous metastases and pleural effusion) * No previous radiation therapy of the only measurable lesion * No previous chemotherapy for metastatic disease; previous adjuvant chemotherapy is permitted if there was no progression of the disease within a period of 6 months * Patients aged 60 years and beyond * Written patient informed consent * ECOG Status 0-2 * Granulocytes \>= 2 x 10\*\*9/l and thrombocytes \>= 100 x 10\*\*/l * Serum creatinine, bilirubin \< 1.5 times the upper limit of normal value, albumin \> 25 g/l * No severe comorbidity including psychosis or any previous history of uncontrolled cardiovascular disease * Normal left-ventricular function by echocardiography or MUGA scan * No symptomatic CNS metastases * Willingness to receive regular follow-up examinations Exclusion Criteria: * Histological grading of malignancy: G I * Histology of gastrointestinal stromal tumor, chondrosarcoma, uterine stromal sarcoma, mesothelioma, neuroblastoma, osteosarcoma, Ewing´s sarcoma/PNET, desmoplastic round cell tumor, embryonal rhabdomyosarcoma, alveolar soft tissue sarcoma * Less than 5 years free of secondary malignancy except adequately treated carcinoma in situ (CIS) of the cervix, the bladder urothelium, basal cell carcinoma, or adenoma of the colon including pTIS, pTIN